Among the 6 known glypicans, glypican-1 (GPC1) has gained significant attention because of its aberrant expression in several types of cancer, including pancreatic, breast, and uterine cervical cancers, as well as esophageal squamous cell carcinoma and cholangiocarcinoma (5–9). Here, GPC1 is linked to cancer.